# Appendix D — i-Demo Chemical Analysis Module Specification (NEW)

> Scope, architecture, and integration requirements for the chemical-analysis module launched in OKR2.

---

## Module Overview

The chemical-analysis module extends the BRA platform with compound-level intelligence. It adds 5 sub-modules that plug into existing BRA pipeline steps, enriching benefit-risk assessments with molecular, pharmacokinetic, and pharmacodynamic data.

---

## Sub-Module Specifications

### 1. Compound Search

| Field | Value |
|---|---|
| **Purpose** | Retrieve compound data by name, SMILES, InChI, or CAS number |
| **Inputs** | Compound identifier (any format) |
| **Outputs** | Molecular structure, molecular weight, classification, properties, synonyms |
| **Data Sources** | TBD — owner to fill Wk1 (e.g., ChEMBL, PubChem, DrugBank) |
| **Integration Point** | BRA Step 1 — Context (enriches therapeutic options with compound data) |
| **Performance Target** | < 2 s response time per query |

### 2. ADMET Prediction

| Field | Value |
|---|---|
| **Purpose** | Predict Absorption, Distribution, Metabolism, Excretion, Toxicity profiles |
| **Inputs** | Compound structure (SMILES or structure from Compound Search) |
| **Outputs** | ADMET profile: absorption score, BBB penetration, CYP metabolism, renal clearance, hERG toxicity, hepatotoxicity flags |
| **Model** | TBD — owner to fill Wk1 (ML model or API-based prediction) |
| **Integration Point** | BRA Step 2 — B&R Assessment (feeds safety/risk scoring) |
| **Validation Criteria** | ≥ 80 % accuracy on benchmark dataset of known ADMET profiles |

### 3. Mechanism of Action

| Field | Value |
|---|---|
| **Purpose** | Map drug-target interactions, pathways, pharmacodynamics |
| **Inputs** | Compound identifier |
| **Outputs** | Target proteins, pathway diagram, pharmacodynamic description, mechanism category |
| **Data Sources** | TBD — owner to fill Wk1 (e.g., UniProt, KEGG, Reactome) |
| **Integration Point** | BRA Step 1 — Context + Step 2 — B&R Assessment (explains therapeutic rationale) |
| **Performance Target** | < 5 s per compound |

### 4. Bioactivity Analysis

| Field | Value |
|---|---|
| **Purpose** | Retrieve and display bioactivity data: IC50/EC50, dose-response, selectivity |
| **Inputs** | Compound identifier + target (optional) |
| **Outputs** | IC50/EC50 values, dose-response curves, selectivity matrix, assay metadata |
| **Data Sources** | TBD — owner to fill Wk1 (e.g., ChEMBL bioactivity database) |
| **Integration Point** | BRA Step 3 — Data Analysis (quantitative evidence layer) |
| **Performance Target** | < 3 s per query |

### 5. Drug-Target Binding

| Field | Value |
|---|---|
| **Purpose** | Predict binding affinity, off-target risks, structural docking |
| **Inputs** | Compound structure + target protein |
| **Outputs** | Binding affinity (Kd), off-target predictions, docking score, structural visualization |
| **Model** | TBD — owner to fill Wk1 (docking algorithm or ML prediction) |
| **Integration Point** | BRA Step 5 — Decision-Support (risk/benefit trade-off inputs) |
| **Validation Criteria** | ≥ 75 % accuracy on benchmark binding dataset |

---

## Architecture

```
BRA Platform
├── Step 1: Context
│   ├── [existing] Therapeutic options
│   └── [NEW] Compound Search → Mechanism of Action
├── Step 2: B&R Assessment
│   ├── [existing] Safety/Efficacy endpoints
│   └── [NEW] ADMET Prediction → risk scoring
├── Step 3: Data Analysis
│   ├── [existing] Endpoint data analysis
│   └── [NEW] Bioactivity Analysis → quantitative evidence
├── Step 4: Reporting
│   └── [existing + NEW] Compound data included in reports
└── Step 5: Decision-Support
    ├── [existing] Benefit-risk balance
    └── [NEW] Drug-Target Binding → trade-off inputs
```

---

## API Requirements

| Requirement | Specification |
|---|---|
| **API style** | RESTful, JSON responses |
| **Authentication** | Same as BRA platform (existing auth layer) |
| **Rate limits** | ≥ 100 queries/min per user |
| **Response time** | < 5 s for any single sub-module query |
| **Error handling** | Graceful degradation — if a sub-module is unavailable, BRA continues without it |
| **Data freshness** | Compound databases updated at least monthly |

---

## Validation Requirements

| Validation Type | Method | Minimum Criteria | Owner |
|---|---|---|---|
| **Internal** | Test with 20+ known compounds, compare output to reference data | ≥ 90 % accuracy on known outputs | Data-Team |
| **External** | KOL / early-access client review of 3 case study outputs | ≥ 80 % expert agreement | Vassili |
| **LLM** | Automated validation prompts comparing module output to literature | ≥ 85 % consistency score | Data-Team |

---

## Case Study Selection Criteria

Select 3 compounds for launch case studies that satisfy:

1. **Well-characterized:** extensive published ADMET, bioactivity, and mechanism data (for validation)
2. **Relevant therapeutic area:** aligns with Top-10 target accounts' focus areas
3. **Compelling narrative:** clear benefit-risk trade-off that demonstrates module value
4. **Data available:** all 5 sub-modules can return meaningful results

---

## Cross-References

- [O2 — i-Demo Chemical Analysis Strategy](../Strategies/O2-iDemo-Chemical-Analysis.md)
- [C9 — i-Demo Launch Runbook](../Part-C-Execute/C9-iDemo-Launch-Runbook.md)
- [C4 — Chemical-Analysis Monetization Playbook](../Part-C-Execute/C4-Chemical-Analysis-Monetization-Playbook.md)
- [Appendix-A — Key Definitions](Appendix-A-Key-Definitions.md)

---

*ArcaScience OKR2 Execution Blueprint — Appendix*
